Connor, Clark & Lunn Investment Management (CC&L)
VTYX

Connor, Clark & Lunn Investment Management (CC&L)’s Ventyx Biosciences VTYX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,203,997
Closed -$10.9M – 1784
2025
Q4 		$10.9M Buy
1,203,997
+144,174
+14% +$1.08M 0.03% 445
2025
Q3 		$3.3M Buy
1,059,823
+114,617
+12% +$304K 0.01% 701
2025
Q2 		$2.02M Buy
945,206
+73,601
+8% +$119K 0.01% 860
2025
Q1 		$1M Buy
871,605
+78
+0% +$134 ﹤0.01% 950
2024
Q4 		$1.91M Buy
871,527
+409,357
+89% +$928K 0.01% 738
2024
Q3 		$1.01M Buy
462,170
+42,600
+10% +$98K ﹤0.01% 885
2024
Q2 		$969K Sell
419,570
-56,049
-12% -$233K ﹤0.01% 850
2024
Q1 		$2.62M Buy
475,619
+244,967
+106% +$1.12M 0.01% 604
2023
Q4 		$570K Buy
230,652
+166,708
+261% +$1.58M ﹤0.01% 1012
2023
Q3 		$2.22M Buy
63,944
+37,240
+139% +$1.29M 0.01% 591
2023
Q2 		$876K Buy
+26,704
New +$921K ﹤0.01% 833

Other funds holding VTYX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VTYX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,203,997 shares — an estimated $10.9M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VTYX in Q2 2023 and held it in 11 quarters. The position peaked at $10.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,203,997 Ventyx Biosciences shares in Q1 2026, an estimated $10.9M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Ventyx Biosciences in Q2 2023 and held it in 11 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Ventyx Biosciences position peaked at $10.9M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.